Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin.


Journal

Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971

Informations de publication

Date de publication:
04 2021
Historique:
revised: 29 03 2021
received: 12 10 2020
accepted: 07 04 2021
entrez: 1 5 2021
pubmed: 2 5 2021
medline: 15 1 2022
Statut: ppublish

Résumé

Ferroptosis is essential to regulate tumor growth and serves as a promising therapeutic target to lung cancer. Ubiquitin-specific protease 35 (USP35) belongs to the deubiquitinases family that is associated with cell proliferation and mitosis. In this research, we aim to elucidate the potential role and molecular basis of USP35 in lung cancer. Lung cancer cells were infected with lentiviral vectors to silence or overexpress USP35. Cell viability, colony formation, lipid reactive oxygen species production, intracellular iron metabolism, and other ferroptotic markers were detected. The role of USP35 on ferroptosis and tumor progression were also tested in mouse tumor xenograft models in vivo. USP35 was abundant in human lung cancer tissues and cell lines. USP35 knockdown promoted ferroptosis, and inhibited cell growth, colony formation, and tumor progression in lung cancer cells. USP35 overexpression did not affect tumorigenesis and ferroptosis under basal conditions, but reduced erastin/RSL3-triggered iron disturbance and ferroptosis, thereby facilitating lung cancer cell growth and tumor progression. Further studies determined that USP35 directly interacted with ferroportin (FPN) and functioned as a deubiquitinase to maintain its protein stability. More importantly, we observed that USP35 knockdown sensitized lung cancer cells to cisplatin and paclitaxel chemotherapy. USP35 modulates ferroptosis in lung cancer via targeting FPN, and it is a promising therapeutic target to lung cancer.

Sections du résumé

BACKGROUND
Ferroptosis is essential to regulate tumor growth and serves as a promising therapeutic target to lung cancer. Ubiquitin-specific protease 35 (USP35) belongs to the deubiquitinases family that is associated with cell proliferation and mitosis. In this research, we aim to elucidate the potential role and molecular basis of USP35 in lung cancer.
METHODS
Lung cancer cells were infected with lentiviral vectors to silence or overexpress USP35. Cell viability, colony formation, lipid reactive oxygen species production, intracellular iron metabolism, and other ferroptotic markers were detected. The role of USP35 on ferroptosis and tumor progression were also tested in mouse tumor xenograft models in vivo.
RESULTS
USP35 was abundant in human lung cancer tissues and cell lines. USP35 knockdown promoted ferroptosis, and inhibited cell growth, colony formation, and tumor progression in lung cancer cells. USP35 overexpression did not affect tumorigenesis and ferroptosis under basal conditions, but reduced erastin/RSL3-triggered iron disturbance and ferroptosis, thereby facilitating lung cancer cell growth and tumor progression. Further studies determined that USP35 directly interacted with ferroportin (FPN) and functioned as a deubiquitinase to maintain its protein stability. More importantly, we observed that USP35 knockdown sensitized lung cancer cells to cisplatin and paclitaxel chemotherapy.
CONCLUSION
USP35 modulates ferroptosis in lung cancer via targeting FPN, and it is a promising therapeutic target to lung cancer.

Identifiants

pubmed: 33931967
doi: 10.1002/ctm2.390
pmc: PMC8087931
doi:

Substances chimiques

Cation Transport Proteins 0
metal transporting protein 1 0
Endopeptidases EC 3.4.-
USP35 protein, human EC 3.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e390

Informations de copyright

© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Références

Cancer Lett. 2018 Oct 1;433:186-198
pubmed: 29981430
Cell Signal. 2020 Aug;72:109665
pubmed: 32353410
Acta Pharm Sin B. 2019 Mar;9(2):294-303
pubmed: 30976491
Acta Pharmacol Sin. 2021 Apr;42(4):573-584
pubmed: 32694761
Oncol Lett. 2019 Mar;17(3):3001-3008
pubmed: 30854078
Cell Death Differ. 2019 Dec;26(12):2516-2519
pubmed: 31543514
Science. 2020 Apr 3;368(6486):85-89
pubmed: 32241947
Cell Death Differ. 2020 Feb;27(2):540-555
pubmed: 31209361
Methods Enzymol. 1994;233:202-12
pubmed: 8015457
Cell Death Differ. 2020 Sep;27(9):2635-2650
pubmed: 32203170
Cell Biol Toxicol. 2021 Apr;37(2):209-228
pubmed: 32562082
Cell Death Differ. 2020 Jun;27(6):1747-1764
pubmed: 31748695
Acta Pharmacol Sin. 2020 Jan;41(1):93-100
pubmed: 31285534
Nat Immunol. 2019 Apr;20(4):433-446
pubmed: 30804553
Cell Biol Toxicol. 2020 Oct 10;:
pubmed: 33040242
Cell Death Differ. 2021 Jan;28(1):139-155
pubmed: 32678307
Theranostics. 2020 Feb 19;10(8):3767-3778
pubmed: 32206121
Redox Biol. 2020 Oct;37:101736
pubmed: 33032073
Clin Transl Med. 2019 Jan 19;8(1):4
pubmed: 30661185
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cell Death Differ. 2019 Jan;26(1):14-24
pubmed: 30082768
Cancer Lett. 2019 Nov 1;464:56-61
pubmed: 31437477
Cancer Lett. 2020 Apr 1;474:94-105
pubmed: 31954771
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Cell Death Differ. 2019 Nov;26(11):2300-2313
pubmed: 30778200
Cancer Res Treat. 2018 Apr;50(2):445-460
pubmed: 28494534
Annu Rev Biochem. 2009;78:363-97
pubmed: 19489724
J Mol Med (Berl). 2016 Mar;94(3):347-59
pubmed: 26560875
Cell Death Differ. 2019 Nov;26(11):2284-2299
pubmed: 30737476
Cell Death Differ. 2018 Nov;25(10):1855-1869
pubmed: 29867130
Cell Death Differ. 2019 Mar;26(4):728-740
pubmed: 29899379
Nat Cell Biol. 2014 Dec;16(12):1180-91
pubmed: 25402683
Cell Death Differ. 2020 Feb;27(2):662-675
pubmed: 31273299
Signal Transduct Target Ther. 2020 May 8;5(1):51
pubmed: 32382060
Cancer Lett. 2014 Sep 1;351(2):265-71
pubmed: 24983493
Nat Commun. 2018 Feb 15;9(1):688
pubmed: 29449677
Acta Pharm Sin B. 2019 Nov;9(6):1163-1173
pubmed: 31867162
Acta Pharm Sin B. 2020 Aug;10(8):1534-1548
pubmed: 32963948
Autophagy. 2015 Apr 3;11(4):595-606
pubmed: 25915564
Cell Biol Toxicol. 2020 Aug;36(4):349-364
pubmed: 31907687
Oncotarget. 2015 Sep 29;6(29):27891-906
pubmed: 26348204
Nat Commun. 2020 Jan 23;11(1):433
pubmed: 31974380
Cancer Lett. 2018 Jul 28;427:74-84
pubmed: 29702194
Int J Biol Sci. 2020 Feb 21;16(8):1403-1416
pubmed: 32210728
Int J Biol Sci. 2019 Jan 1;15(3):556-567
pubmed: 30745842
Dev Cell. 2019 Dec 2;51(5):575-586.e4
pubmed: 31735663
Cell Biol Toxicol. 2021 Jan 20;:
pubmed: 33469864
Cell Metab. 2012 Jun 6;15(6):918-24
pubmed: 22682227
Cell Death Differ. 2019 Jul;26(7):1235-1250
pubmed: 30254375
Theranostics. 2020 Jun 19;10(17):7775-7786
pubmed: 32685019
Cancer Res. 2019 Apr 15;79(8):1913-1924
pubmed: 30709928
Cell Biol Toxicol. 2020 Oct 17;:
pubmed: 33070227
Cell Death Differ. 2018 Jun;25(6):1050-1062
pubmed: 29472714
Arch Toxicol. 2019 Jun;93(6):1555-1571
pubmed: 30993382
Clin Transl Med. 2021 Apr;11(4):e390
pubmed: 33931967
Cardiovasc Res. 2019 May 1;115(6):1067-1077
pubmed: 30407523
Redox Biol. 2020 Oct;37:101747
pubmed: 33045622
Cell Death Dis. 2018 Jan 24;9(2):102
pubmed: 29367637
Cell Metab. 2005 Mar;1(3):155-7
pubmed: 16054057
Cell Biol Toxicol. 2019 Jun;35(3):233-245
pubmed: 31140025
Clin Transl Med. 2020 Jul;10(3):e124
pubmed: 32618439
Cell Death Differ. 2019 Nov;26(11):2329-2343
pubmed: 30787392
Acta Pharm Sin B. 2019 Jul;9(4):690-701
pubmed: 31384530
Cell Mol Life Sci. 2016 Jun;73(11-12):2195-209
pubmed: 27048822
Cell Biol Toxicol. 2020 Nov 1;:
pubmed: 33131013
Theranostics. 2019 Apr 6;9(7):2084-2099
pubmed: 31037158
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970

Auteurs

Zheng Tang (Z)

Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

Wanli Jiang (W)

Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Ming Mao (M)

Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

Jinping Zhao (J)

Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

Jiakuan Chen (J)

Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

Nitao Cheng (N)

Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH